trending Market Intelligence /marketintelligence/en/news-insights/trending/etvMTk-KQ2GIQo56k0HYWA2 content esgSubNav
In This List

EyeGate Pharma to implement 1-for-15 reverse stock split

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


EyeGate Pharma to implement 1-for-15 reverse stock split

EyeGate Pharmaceuticals Inc.'s board approved a 1-for-15 reverse split for the company's common stock in order to come under compliance with the Nasdaq Capital Market's listing requirements.

The reverse split will become effective on Aug. 30, at 12:01 a.m. ET and the stock will begin trading on a split-adjusted basis.

Waltham, Mass.-based EyeGate is a clinical-stage pharmaceutical company that develops therapies to treat eye-related diseases and disorders.

VStock Transfer LLC will act as exchange agent for the reverse split.